

1 **Rapid Biphasic Decay of Intact and Defective HIV DNA**

2 **Reservoir During Acute Treated HIV Disease**

3  
4 Alton Barbehenn<sup>1</sup>, Lei Shi<sup>2</sup>, Junzhe Shao<sup>2</sup>, Rebecca Hoh<sup>1</sup>, Heather M. Hartig<sup>1</sup>, Vivian Pae<sup>1</sup>,  
5 Sannidhi Sarvadhavabhatla<sup>1</sup>, Sophia Donaire<sup>1</sup>, Caroline Sheikhzadeh<sup>1</sup>, Jeffrey Milush<sup>5</sup>, Gregory  
6 M. Laird<sup>3</sup>, Mignot Mathias<sup>3</sup>, Kristen Ritter<sup>3</sup>, Michael Peluso<sup>1</sup>, Jeffrey Martin<sup>4</sup>, Frederick Hecht<sup>1</sup>,  
7 Christopher Pilcher<sup>1</sup>, Stephanie E. Cohen<sup>1,6</sup>, Susan Buchbinder<sup>6</sup>, Diane Havlir<sup>1</sup>, Monica  
8 Gandhi<sup>1</sup>, Timothy J. Henrich<sup>5</sup>, Hiroyu Hatano<sup>1</sup>, Jingshen Wang<sup>2</sup>, Steven G. Deeks<sup>1</sup>, and Sulggi  
9 A. Lee<sup>\*1</sup>

10  
11 <sup>1</sup>Department of Medicine, Division of HIV, Infectious Diseases & Global Medicine, University of  
12 California San Francisco, San Francisco, CA 94110, USA. <sup>2</sup>Department of Biostatistics,  
13 University of California Berkeley, Berkeley, CA 94110, USA. <sup>3</sup>AcceleVirDiagnostics, Baltimore,  
14 MD 21202, USA. <sup>4</sup>Department of Biostatistics & Epidemiology, University of California San  
15 Francisco, CA 94158, USA. <sup>5</sup>Department of Medicine, Division of Experimental Medicine,  
16 University of California San Francisco, San Francisco, CA 94110, USA. <sup>6</sup>San Francisco  
17 Department of Public Health, San Francisco, CA 94102, USA.

18  
19 #Co-Lead Authors: Alton Barbehenn and Lei Shi

20 \*Corresponding Author: [sulggi.lee@ucsf.edu](mailto:sulggi.lee@ucsf.edu)

21 **ABSTRACT**

22 Antiretroviral therapy (ART) is not a cure. Upon ART cessation, virus rapidly rebounds from  
23 latently-infected cells (“the HIV reservoir”). The reservoir is largely stabilized at the time of ART  
24 initiation and then decays slowly. Here, leveraging >500 longitudinal samples from 67 people  
25 with HIV (PWH) treated during acute infection, we developed a novel mathematical model to  
26 predict reservoir decay using the intact proviral DNA assay (IPDA) from peripheral CD4+ T cells.  
27 Nonlinear generalized additive models adjusted for initial CD4+ T count, pre-ART viral load, and  
28 timing of ART initiation demonstrated rapid biphasic decay of intact DNA (week 0-5:  $t_{1/2}$  ~0.71  
29 months; week 5-24:  $t_{1/2}$  ~3.9 months) that extended out to 1 year of ART, with similar trends for  
30 defective DNA. Predicted reservoir decay were faster for participants individuals with earlier  
31 timing of ART initiation, higher initial CD4+ T cell count, and lower pre-ART viral load. These  
32 estimates are ~5-fold faster than prior reservoir decay estimates among chronic-treated PWH.  
33 Thus, these data add to our limited understanding of host viral control at the earliest stages of  
34 HIV reservoir stabilization, potentially informing future HIV cure efforts aimed at diverse, global  
35 population of PWH initiating ART at varying stages of disease.

36

37 Abstract Word Count (approx. 150): 198

38

39 **Title Word Count** (max 15): 15

40 **Manuscript Word Count** (5000; Methods 3,000 words): 4,122

41 **Keywords:** acute HIV; antiretroviral therapy (ART); HIV reservoir decay; pre-exposure  
42 prophylaxis (PrEP)

43 **CONFLICTS:** The authors do not have a commercial or other association that might pose a  
44 conflict of interest.

45 **FUNDING:** This work was supported in part by the National Institutes of Health: K23GM112526  
46 (SAL), the DARE Collaboratory (UM1AI164560; SGD), the AcceleVirDx HIV Reservoir Testing  
47 Resource (U24AI143502; GML), and NIH/NIAID R01A141003 (TJH). This work was also  
48 supported by the amfAR Research Consortium on HIV Eradication a.k.a. ARCHE (108072-50-  
49 RGRL; SGD), the Bill & Melinda Gates Foundation (INV-002703; SGD), and investigator-  
50 initiated research grants from ViiV Healthcare (A126326; SAL) and Gilead Sciences (IN-US-  
51 236-1354; SAL). The content of this publication does not necessarily reflect the views or policies  
52 of the Department of Health and Human Services, the San Francisco Department of Health, nor  
53 does mention of trade names, commercial products, or organizations imply endorsement by the  
54 U.S. Government. The funders had no role in study design, data collection and analysis,  
55 decision to publish, or preparation of the manuscript.

56 **Previous presentation:** Preliminary data were presented in July 2023, as a poster presentation  
57 at the International AIDS Society (IAS) conference in Brisbane, Australia.

58 **Reprints:** Reprint requests can be directed to Dr. Sulggi Lee, the corresponding author (contact  
59 information above).

60 **Acknowledgements:**

61 The authors wish to acknowledge the participation of all the study participants who contributed  
62 to this work as well as the clinical research staff of the UCSF Treat Acute HIV and SCOPE

63 cohorts who made this research possible. All funders had no role in study design, data  
64 collection and analysis, decision to publish, or preparation of the manuscript. All authors  
65 provided critical feedback in finalizing the report. HH, SGD, and SAL conceived and designed  
66 the study. HH, SGD, and SAL obtained funding to support the clinical enrollment of study  
67 participants, and SAL and SGD obtained funding to support characterization of the HIV  
68 reservoir. SEC, SB, DH, and MG facilitated coordination with San Francisco Department of  
69 Public Health and Ward 86 clinical services to link patients into care and provided critical  
70 feedback on the clinical management of acute HIV. SAL, RH, SGD, TJH, HMH, SS, SD, and VP  
71 coordinated the collection, management, and quality control processes for the clinical data, and  
72 SAL, SGD, JM, FH, and CP provided biospecimens. JM and TJH performed biospecimen  
73 processing, GML, MM, and KR performed the HIV reservoir assays. LS developed the initial  
74 decay models, under the guidance of SAL and JW, and AB and SAL further modified these  
75 models under the guidance of JW, LS, and JS. GML, MM, KR, LS, JS, JW, and SAL analyzed  
76 the HIV reservoir data. SAL, AB, LS, and JW wrote the report. SS, SD, VP, CS, LS, JS, JW, and  
77 SAL finalized data visualization for the manuscript. All authors provided critical feedback in  
78 finalizing the manuscript.

## 79 INTRODUCTION

80 Despite over four decades of research, we do not yet have an HIV cure. While  
81 antiretroviral therapy (ART) is able to suppress virus to undetectable levels, virus rapidly  
82 rebounds from latently-infected cells (“the HIV reservoir”) within weeks of ART interruption.<sup>1-8</sup>  
83 Thus, a major goal is to eradicate and/or accelerate the decay of the reservoir in order to  
84 achieve clinical remission. However, HIV cure trials to date have largely failed to demonstrate a  
85 clinically meaningful reduction in the size of the HIV reservoir and/or lead to sustained ART-free  
86 remission.<sup>9-12</sup> The majority of these trials have been conducted among people with HIV (PWH)  
87 treated during chronic infection and were administered therapeutic interventions long after the  
88 reservoir was established (i.e., several years after initiating ART)<sup>13-18</sup>. Recent combination  
89 therapy trials (e.g., broadly neutralizing antibodies given with ART) have yielded more promising  
90 results, and a few participants have demonstrated evidence of extended ART-free viral control<sup>19-</sup>  
91 <sup>21</sup>, but the mechanisms by which these small number of participants exhibit enhanced viral  
92 control remain unclear.

93 One possibility is that since PWH treated during chronic HIV often have larger  
94 reservoirs<sup>22-29</sup> and exhausted/dysfunctional immune responses<sup>30-32</sup> (due to prolonged periods of  
95 untreated HIV infection), that demonstrating measurable HIV remission from these small trials  
96 may have been more challenging. Indeed, individuals who initiate ART “earlier” (within 6 months  
97 after infection) may be more likely to become “post-treatment controllers” (PTCs), rare PWH  
98 who, for unclear reasons, are able to control virus without ART following a brief of initial ART  
99 suppression.<sup>33</sup> Thus, different host factors, such as timing of ART initiation in relation to  
100 chronicity of HIV infection, initial CD4+ T cell count, or pre-ART HIV viral load, may have  
101 profound impact on estimating HIV reservoir decay rates, and yet there are limited data  
102 modeling decay rates while accounting for these factors. Such information would be immensely  
103 useful in future HIV cure trials to compare expected reservoir decay rates in comparison to

104 curative interventions and allow generalizability of findings to a more global population of PWH  
105 (treated during acute or chronic infection).

106 While there have now been a handful of studies modeling how quickly the HIV reservoir  
107 decays during prolonged ART (studies spanning nearly 20 years on ART)<sup>34-37</sup>, there have been  
108 no studies modeling HIV reservoir decay rates after acute treated HIV infection. Here,  
109 leveraging ~500 longitudinal blood measurements of the HIV reservoir, we developed a novel  
110 mathematical model of reservoir decay among 67 participants from the UCSF Treat Acute HIV  
111 cohort initiating ART within 100 days of the estimated date of HIV infection.<sup>38</sup> These data  
112 demonstrate for the first time that the reservoir decays significantly faster in acute compared to  
113 chronic treated PWH initiating ART.<sup>3</sup> Our partially parameterized mathematical model flexibly  
114 estimated the rate of change of the HIV reservoir to include participant-level random effects (to  
115 account for heterogeneity in decay rates) as well as key clinical covariates (initial CD4+ T count,  
116 pre-ART viral load, and days since estimated date of HIV infection).

117 We fit various mono-, bi-, and triphasic decay curves for both HIV “intact” (infected cells  
118 harboring intact viral sequences able to produce infectious virions) and “defective” (the majority  
119 of the HIV reservoir but incapable of producing infectious virions) DNA. For both intact and  
120 defective DNA, we observed clear biphasic decay patterns with an initial rapid first phase of  
121 decay (which was nearly identical to previous estimates in chronic treated PWH initiating ART<sup>3</sup>)  
122 followed by a second slower phase of decay (~5-fold faster than previously reported in chronic  
123 PWH initiating ART). Furthermore, these decay rates were significantly faster among individuals  
124 with known clinical factors associated with enhanced host viral control: higher initial CD4+ T cell  
125 count, earlier initiation of ART, and lower pre-ART viral loads.<sup>22,23,34,39,40</sup> These data are the first  
126 to our knowledge to describe a predictive mathematical model to describe HIV reservoir decay  
127 rates during acute treated HIV.

128

## 129 **RESULTS**

## 130 **Characteristics of study participants**

131 A total of 67 adults (83% of those screened) with a new diagnosis of acute HIV (<100  
132 days between the estimated date of detected HIV infection to the baseline study visit/ART  
133 initiation) were included in the UCSF Treat Acute HIV cohort (**Table 1, Supplementary Figure**  
134 **1**)<sup>41</sup>. All 67 participants completed follow-up in the study for the full 24 weeks. A large  
135 proportion (65.7%) of participants co-enrolled in our longitudinal UCSF SCOPE HIV cohort and  
136 remained in study for additional follow-up, with study visits approximately every 3-4 months  
137 thereafter. Follow-up for the current analysis included longitudinal sampling for a median of 0.81  
138 years. The estimated dates of detected infection (EDDI) were calculated to determine recency  
139 of infection using the Infection Dating Tool (<https://tools.incidence-estimation.org/idt/>)<sup>42</sup>  
140 (**Supplementary Figure 2**). These estimates were then used to estimate acute HIV Fiebig  
141 stages<sup>43,44</sup>. Consistent with our San Francisco-based study population, participants were mostly  
142 male (97%) and reflected local and national racial/ethnic trends of higher incident acute HIV in  
143 these populations<sup>45</sup>. Baseline study visit HIV-1 antigen/antibody (Architect) and HIV-1 antibody  
144 (Geenius) testing demonstrated 27% and 28% false negative/indeterminate rates, respectively,  
145 consistent with our San Francisco Department of Public Health (SFDPH) reported estimates for  
146 new acute HIV diagnoses<sup>46</sup> (**Supplementary Figure 4**). Genotype data (Monogram) were  
147 available for a subset of 57 participants; 77% had wild-type HIV, 9% had M184V/I mutations (all  
148 were reported among participants citing prior and/or current PrEP use), and 14% had evidence  
149 of possible partner-transmitted resistance mutations (based on referral of newly diagnosed  
150 partners within our cohort and/or SFDPH partner tracing<sup>46</sup>).

151 Our cohort also reflected a high proportion of self-reported prior PrEP use (42%  
152 reporting ever use while 20% reported PrEP use in the past 10 days), reflecting San Francisco's  
153 early and widespread adoption of PrEP<sup>46</sup>. All PrEP reported in this study was oral PrEP with  
154 tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), as this was the only form clinically  
155 available during the study period. Among individuals reporting overlapping PrEP use within 10

156 days from their estimated date of HIV acquisition (using self-reported PrEP use and the infection  
157 dating tool as described in the Methods <sup>42</sup>), six participants were deemed to have probable HIV  
158 acquisition while on PrEP (median baseline plasma log<sub>10</sub>HIV RNA = 2.2 copies/mL), which was  
159 approximately ~3 log<sub>10</sub> lower than those not reporting PrEP overlap (**Table 1**). One participant  
160 was estimated to have acquired HIV in the setting of therapeutic PrEP concentrations  
161 (confirmed by plasma and hair ART concentrations), as described in our previous publication <sup>47</sup>.

162

### 163 **Rapid biphasic decay of intact and defective DNA**

164 We estimated the rate of change of HIV intact and defective DNA as log<sub>10</sub>copies per 10<sup>6</sup>  
165 peripheral CD4+ T cells (quantified using the IPDA), as well as the influence of clinical  
166 covariates on the rate of HIV DNA change. A median of 2 x 10<sup>6</sup> CD4+ T cells per sample  
167 (median viability of 97%) was recovered from peripheral CD4+ T cells isolated by negative  
168 immunomagnetic selection. Duration of ART was used as the primary predictor to allow for time-  
169 varying estimation of changes within each person across the sampling timepoints. The rate of  
170 change was estimated for the primary outcome of HIV intact DNA, as well as the secondary  
171 outcome of defective DNA (3' defective, 5' defective, and total combined defective provirus). We  
172 initially modeled HIV intact and defective DNA using a linear effect of time on ART (which  
173 assumes a constant rate of change regardless of the duration of viral suppression). However,  
174 we observed evidence of nonlinearity, and thus, instead of fitting a single constant rate of  
175 decline, we fit nonlinear generalized additive models to estimate the appropriate nonparametric  
176 relationship for each predictor term.

177 Clinical covariates of age, gender, pre-ART CD4+ T cell count, pre-ART viral load, and  
178 timing of ART initiation (number of weeks since estimated date of infection) were tested for  
179 inclusion in these models. Final models included terms for initial CD4+ T cell count, pre-ART  
180 viral load, and timing of ART initiation. **Figure 4** illustrates that of the three clinical covariates,  
181 only timing of ART initiation changes the shape of the reservoir decay, whereas initial CD4+ T



182 cell count and pre-ART viral load account for patient-level variation. Additionally, we added  
183 individual participant-level random effects into regression models to account for heterogeneity in  
184 outcome measures within individuals (see **Statistical Methods**). Given the small number of  
185 participants reporting PrEP use within 10 days of HIV acquisition (**Table 1**), inclusion of this  
186 parameter as a covariate in the model and sensitivity analyses excluding these individuals did  
187 not change results, and thus was not included as a covariate in final models. In addition,  
188 participants reporting potential PrEP overlap did not clearly fall in the lower range of reservoir  
189 measurements, but rather, were dispersed among the range of HIV intact and defective DNA  
190 values (**Supplementary Figure 5**).

191 Therefore, we then fit various mono-, bi-, and triphasic decay curves for both HIV intact  
192 and defective DNA using semiparametric generalized additive models that introduced up to two  
193 inflection points, tau ( $\tau$ ), delineating distinct exponential decay phases (see **Statistical**  
194 **Methods**). We then estimated the decay model's inflection points  $\tau$  by minimizing prediction  
195 errors as measured by leave-one-out mean absolute deviation (MAD) and leave-one-out mean  
196 squared error (MSE) approaches (**Figure 2, Supplementary Figure 7**). For HIV intact DNA, we  
197 found that the biphasic model best fit our data, while for defective DNA, the biphasic and  
198 triphasic models were relatively equivalent in performance (**Supplementary Figure 6**). A  
199 biphasic model outperformed a monophasic decay model for both intact and defective DNA.  
200 These analyses demonstrated that  $\tau = 5$  weeks closely fit our data using this biphasic model. To  
201 ensure that the selected  $\tau = 5$  was not influenced by potential outlier data, we performed three  
202 different sensitivity analyses excluding (1) individuals reporting prior PrEP use within 10 days of  
203 estimated date of HIV infection, (2) participants with plasma viral load "blips" (defined as a one-  
204 time viral load  $>1000$  copies/mL or two consecutive viral loads  $>100$  copies/mL between weeks  
205 0-24), and (3) participants with sudden increases in HIV intact DNA (defined as  $>50\%$  increase  
206 between two consecutive measurements of HIV intact DNA during weeks 0-24). These

207 sensitivity analyses demonstrated that  $\tau = 5$  is a reasonable choice for the mode  $l$ 's inflection  
208 point and that the model estimates were unchanged after excluding these potential outliers.

209         Based on our final selected multivariate model, we observed a rapid biphasic decay of  
210 both intact and defective DNA during acute treated HIV infection, with an initial steep decay until  
211 approximately 5 weeks of ART, followed by a slower decay (**Figure 1a**). For example, for HIV  
212 intact DNA, we estimated that the first phase of reservoir decay had an estimated half-life ( $t_{1/2}$ )  
213  $\sim 0.70$  (95% confidence interval [CI] = 0.59, 0.82) months in unadjusted models and a  $t_{1/2} \sim 0.71$   
214 (95%CI = 0.60, 0.82) months in models adjusted for clinical covariates. This was followed by a  
215 slower second decay phase after  $\sim 5$  weeks of ART with a  $t_{1/2} \sim 3.61$  (95%CI = 2.81, 4.42)  
216 months in unadjusted models and a  $t_{1/2} \sim 3.86$  (95%CI = 2.99, 4.72) months in models adjusted  
217 for clinical covariates. Similar first phase (weeks 0-5) decay rates were observed for HIV  
218 defective DNA in unadjusted ( $t_{1/2} \sim 0.34$ , 95% CI = 0.29, 0.38) and adjusted ( $t_{1/2} \sim 0.34$ , 95% CI =  
219 0.29, 0.39) models but estimates were less stable for the second phase of defective DNA decay  
220 due to considerable variability in these data (**Figure 1, Supplementary Tables 1-2**). Thus, we  
221 did not observe discernable differences in decay rates for HIV intact versus defective DNA in  
222 the first five weeks after ART initiation, in contrast to prior reservoir decay studies among  
223 chronic treated PWH during nearly 20 years of ART<sup>34-36,48</sup>, although we did see a discernable  
224 differences in decay rates for HIV intact versus defective DNA from weeks 5-24 that seems to  
225 continue out to a year (**Supplementary Figure 7**).

226         For all models, fitted values closely predicted observed values for both intact and  
227 defective DNA (**Supplementary Figure 10**). We further validated our models using our clinical  
228 data to determine whether our model captured expected clinical relationships. Our model tells  
229 us that for every additional week ART initiation is delayed, the half-life for the first phase of HIV  
230 intact reservoir decay increases by  $\sim 0.02$  months; similarly, the defective reservoir's half-life  
231 increases by  $\sim 0.01$  months. Importantly, our model tells us that the timing of ART initiation has a  
232 larger impact on the second phase of HIV reservoir decay. During weeks 5-24, our model

233 predicts an increase in intact reservoir decay half-life of ~0.27 months for every week delay in  
234 ART initiation and no significant change to the defective HIV reservoir (**Supplementary Table**  
235 **3**). Concretely, this means that a patient who initiates ART 30 days post infection has an  
236 average intact HIV reservoir decay half-life of ~2.5 months while a patient who initiates ART 100  
237 days post infection has an average intact HIV reservoir decay half-life of ~6.3 months; as  
238 suggested in **Supplementary Figure 7**, this may continue out to a year on ART. Clinical  
239 validation of the initial CD4+ T cell count and pre-ART viral load terms is more straightforward  
240 because they are only used to account for participant-level variation, not changes in half-life.  
241 Our model tells us that both lower pre-ART viral load and higher initial CD4+ T counts were  
242 associated with lower intact and defective HIV DNA reservoirs (**Supplementary Table 4**).  
243 Finally, using bootstrapping methods (random sampling of the clinical covariates to compute  
244 model predictions for 300 new participants) we estimated HIV DNA intact and defective counts  
245 and then averaged the model predictions within strata (tertiles) of each clinical parameter (e.g.,  
246 average HIV intact DNA decay rate for the first, second, and third tertiles of pre-ART viral loads  
247 (**Figure 5**). These analyses clearly demonstrated that our model predicts lower HIV intact and  
248 defective DNA reservoirs for individuals with higher initial CD4+ T cell count and lower pre-ART  
249 viral load, and the HIV intact and defective DNA reservoirs decayed more rapidly for earlier  
250 timing of ART initiation.

251

## 252 **DISCUSSION**

253 The HIV reservoir is established within days after initial viral infection<sup>49-51</sup>, and although  
254 ART can suppress virus to undetectable levels in the blood, persistently cells are a source of  
255 viral rebound when therapy is interrupted. A major goal of HIV cure strategies is to induce ART-  
256 free remission<sup>52</sup>. Thus, clearly defining complex reservoir decay dynamics at the time of HIV  
257 reservoir establishment – including how key host factors such as the timing of ART initiation,  
258 initial CD4+ T cell count, and pre-ART viral load influence these decay rates – will be important

259 in interpreting HIV cure trial results. Potential promising therapeutic interventions may be  
260 optimally studied in specific patient populations, but results from such studies can still inform  
261 future therapies for all PWH. For example, chronic treated PWH may benefit from the same  
262 curative interventions as acute treated PWH but might require adjunctive therapies to reverse  
263 cell exhaustion<sup>53-55</sup>. Here, using a unique cohort of individuals followed longitudinally since acute  
264 HIV infection and immediate ART initiation, we observed a clear biphasic decay of the reservoir  
265 during the first year of therapy. Decay rates were accelerated among individuals with clinical  
266 factors associated with enhanced viral control (higher initial CD4+ T cell count, lower pre-ART  
267 viral load, and earlier timing of ART initiation)<sup>22,23,34,39,40</sup> and were faster than prior reports among  
268 chronic treated PWH initiating ART<sup>3</sup>.

269 Our model allowed flexible estimation of HIV intact and defective decay rates while  
270 adjusting for clinical covariates, in contrast prior studies which mostly fit fully parameterized,  
271 mixed effects models<sup>3,48,56,57</sup>. For example, with HIV intact DNA, the observed initial rapid phase  
272 was estimated to have a half-life ( $t_{1/2}$ ) of 0.71 months until approximately 5 weeks of ART. This  
273 was then followed by a slower second phase of decay with a half-life of 3.86 months. Strikingly,  
274 our estimated decay rate of HIV intact DNA during the first phase of decay is nearly identical to  
275 estimates of HIV intact DNA among chronic treated PWH initiating ART in a prior study ( $t_{1/2}$  =  
276 0.43 months)<sup>3</sup>. However, our estimates for the second phase of decay ( $t_{1/2}$  = 3.9 months) were  
277 ~5-fold faster than reported their study of chronic treated PWH, where the second phase of  
278 decay was estimated to be much longer ( $t_{1/2}$  = 19 months)<sup>3</sup>. This initial rapid decay phase is  
279 thought to reflect death of productively infected cells in the setting of rapid antigen reduction  
280 with ART initiation<sup>4</sup> and thus similarly rapid decay rates immediately after ART initiation may be  
281 similar for PWH who start therapy during acute, as well as chronic infection. Meanwhile, the  
282 second phase of decay is thought to reflect a “contraction phase” when activated cells shift to a  
283 more memory phenotype<sup>58</sup> and therefore, the larger differences that we observed in our cohort

284 compared to earlier findings in chronic-treated PWH may indicate a unique phase during which  
285 intervention may considerably influence HIV reservoir decay rates with earlier ART initiation.

286 PWH treated during acute infection have been shown to have less exhausted/relatively  
287 intact host immune responses due to earlier removal of antigen and reduction of subsequent  
288 inflammation and immune activation.<sup>59</sup> For these reasons, the study of acute treated PWH  
289 provides a unique opportunity to identify the optimal timing, potential “windows of time” during  
290 which intervention with immunomodulatory agents may have a greater impact on reducing the  
291 reservoir size. Most (but not all) studies have shown that those who initiate ART during acute  
292 and early infection also have smaller reservoirs than PWH who initiated ART during chronic  
293 infection<sup>22-26,28,50,51,60</sup>. Given the limited data demonstrating reservoir decay rates during acute  
294 and early infection<sup>26,50,61,62</sup>, none of which included statistical modeling incorporating key clinical  
295 parameters such as timing of ART initiation, initial CD4+ T cell count, and pre-ART viral load,  
296 our data add considerable insight to our current understanding of the timing and modification of  
297 early HIV reservoir establishment and stabilization. Nonetheless, there are a wealth of other  
298 invaluable HIV cohorts, such as the RV254/SEARCH 010 study, that if these data are compiled  
299 across studies, may further inform our understanding of how quickly the reservoir decays, and  
300 how factors such as ART initiation during acute infection may alter those trajectories. Indeed, in  
301 the RV254/SEARCH 010 study, the presented HIV reservoir data (their study measured  
302 integrated and unintegrated HIV DNA) plotted longitudinally, seem to indicate that similar decay  
303 patterns might be observed in their cohort as well.<sup>50</sup> Acute treated PWH in the study  
304 demonstrated rapid decay of both integrated and unintegrated HIV DNA while among chronic  
305 treated PWH in their study, only a modest decline in integrated HIV DNA was observed. (The  
306 latter may be an artifact of the previously noted observation that among chronic PWH, the  
307 majority of integrated HIV DNA tend to be latent or defective, rather than productively infected,  
308 as in acute PWH).<sup>50</sup>

309 While there have been limited studies describing HIV reservoir decay rates in acute  
310 treated PWH, there now been several studies describing HIV reservoir decay rates during  
311 chronic treated HIV (followed as long as ~20 years of ART). These studies have now  
312 demonstrated that cells harboring “intact” provirus (i.e., infected cells capable of producing  
313 infectious virus) decay more quickly than defective provirus (infected cells that make up the  
314 majority of the reservoir and contain deletions and/or mutated viral sequences<sup>63,64</sup>) during long-  
315 term ART<sup>34-37</sup>. While our data are unable to yet describe decay rates past 1 year of ART, our  
316 study offers for the first time a detailed estimation of HIV reservoir decay rates in the first few  
317 weeks to months of ART initiation during acute HIV. While we did not observe discernable  
318 differences between HIV intact and defective decay rates as previously described among  
319 chronic PWH,<sup>34-36,48</sup> we did find that HIV defective DNA was much more “noisy” than intact DNA  
320 (as shown in **Figure 2**), and thus the lack of statistical significance in the second phase of decay  
321 reported here may be further investigated in future larger studies. Indeed, the putative  
322 mechanism underlying the differential decay rates of HIV intact and defective reservoir during  
323 long-term ART is thought to be due to selective immune clearance over time; cells harboring  
324 inducible “replication-competent” virus may be more readily detected by host immune  
325 surveillance and cleared.<sup>34-36,48,65,66</sup> It is unclear if these same factors are at play as early as 5  
326 weeks after initiating ART during acute HIV infection.

327 Studies estimating HIV reservoir decay rates in chronic PWH have shown that the HIV  
328 intact reservoir decays with a  $t_{1/2}$  of ~44 months.<sup>67,68</sup> Subsequent studies studying individuals as  
329 far out as ~20 years of ART suggest that this  $t_{1/2}$  further slows to ~224-276 months after about  
330 7 years of ART.<sup>34-36,48</sup> Interestingly, these long-term follow-up studies have found that during this  
331 late phase of reservoir decay, some individuals appear to demonstrate a plateau, or even a  
332 slight increase, in their HIV intact reservoir size. The reasons for this are unclear but some have  
333 argued that this may be due to a “tipping point” at which the host immune response has cleared

334 the majority of the intact reservoir in the body and is then counterbalanced by ongoing cell  
335 proliferation.<sup>48</sup>

336 While we were able to perform an in-depth statistical modeling study, leveraging unique  
337 acute treated participant samples and a large number of longitudinal HIV reservoir  
338 measurements, our study has several limitations that deserve mention. While the peripheral  
339 HIV reservoir largely reflect infected-cell populations originating from tissues reservoir,<sup>49,50,69,70</sup>  
340 we only included peripheral CD4+ T cell HIV reservoir measures in our model. In addition, while  
341 we used the widely utilized IPDA (a high throughput assay that can be performed on this large  
342 number of samples), alternative assays, such as near-full length proviral sequencing or QVOA,  
343 would have been informative to further interpret our findings (if these were able to be performed  
344 at the scale required for this large number of samples). However, HIV intact DNA measured  
345 using the IPDA has been shown to closely reflect trends resulting from these other assays,  
346 even considering the known enrichment of integrated forms of HIV DNA observed in acute  
347 PWH.<sup>50</sup> As with all molecular assays for HIV, certain polymorphisms at primer or probe binding  
348 sites can impact IPDA assay performance. In this study, we observed IPDA signal failure for 6  
349 of 67 participants (8.9%) – a rate consistent recent reports on very large cohorts of PWH from  
350 North America and Europe where subtype B predominates (6-7%)<sup>34,71</sup>. While the IPDA does not  
351 perfectly discriminate intact from defective proviruses, the cross sectional and longitudinal  
352 correlations between IPDA and QVOA measurements of the HIV reservoir strongly support the  
353 use of the higher throughput IPDA in large scale studies of proviral decay dynamics. We did not  
354 include parameters for potential influences from changes in clonal landscape over time as our  
355 study did not include HIV integration analyses. However, the clonal landscape at the time of  
356 acute HIV is extremely diverse, and we hypothesize that this effect is more likely to have higher  
357 impact after longer duration of ART suppression. Future models should include these  
358 parameters to formally test this hypothesis. Finally, there are few highly characterized acute HIV  
359 cohorts to date, and each study possesses unique host and viral characteristics making direct



360 cross-cohort comparisons challenging. These cohort-specific factors include host genetics,  
361 socio-behavioral demographics (our study included mostly men who have sex with men), clinical  
362 practices and public policy guidelines for ART initiation, and viral subtype (mostly subtype B in  
363 our study). Our HIV reservoir decay model should be further validated in these global  
364 populations, including individuals initiating treatment during chronic HIV, which represents the  
365 majority of people currently living with HIV. Overall, these data encourage future collaborative  
366 work to determine decay dynamics across global populations so that future cure strategies may  
367 be effective across clades and in people with larger reservoirs, exhausted immune responses  
368 who initiated ART during chronic HIV.

369

## 370 **METHODS**

### 371 **Study participants**

372 Individuals with newly diagnosed acute HIV (<100 days from estimated date of infection)  
373 were enrolled in the UCSF Treat Acute HIV cohort between December 1, 2015 to November 30,  
374 2020 and co-enrolled in the UCSF SCOPE HIV cohort, an ongoing longitudinal study of over  
375 2,500 PWH to characterize the natural history of HIV disease. Eligible participants were  
376 consented, provided same-day ART initiation with tenofovir/emtricitabine (TDF/FTC, then  
377 TAF/FTC once available in 2016) + dolutegravir (DTG) and linked to clinical care<sup>46</sup>. Individuals  
378 reporting concomitant PrEP use (<100 days from any potential exposure to HIV by history  
379 and/or clinical test results) were also started on darunavir+ritonavir (DRV/r) as a fourth drug,  
380 which was continued until confirmation of baseline HIV genotyping test results (Monogram  
381 Biosciences, South San Francisco, CA, U.S.A.). Additional ART changes necessary for clinical  
382 care (e.g., laboratory abnormalities, drug-drug interactions, and/or participant preference) were  
383 honored and adjusted during the period of study. Participants signed a release of information



384 which allowed clinical data extraction to determine prior HIV negative test results from the  
385 SFDPH, as well as additional HIV test results.

386 Study participants were seen for monthly study visits for the first 24 weeks and then  
387 every 3-4 months thereafter. Inclusion criteria for the study were prior HIV negative testing  
388 within the last 90 days, laboratory-confirmed HIV-1 infection by antibody/antigen and/or plasma  
389 HIV RNA assay, and willingness to be participate in the study for at least 24 weeks. Participants  
390 with severe renal or hepatic impairment, concurrent treatment with immunomodulatory drugs, or  
391 exposure to any immunomodulatory drugs in the preceding 90 days prior to study entry,  
392 pregnant or breastfeeding women, or participants unwilling to agree to the use a double-barrier  
393 method of contraception throughout the study period, were excluded. For each study participant,  
394 using the Infection Dating Tool (<https://tools.incidence-estimation.org/idt/>)<sup>42</sup>, the estimated date  
395 of detected HIV infection (EDDI), along with a “confidence interval” for early probable (EP-EDDI)  
396 and late probable (LP-EDDI) date was calculated using each participant’s prior clinical HIV test  
397 results, as well the study baseline HIV test results. At each visit, detailed interviews included  
398 questions regarding current medications, medication adherence, intercurrent illnesses, and  
399 hospitalizations were performed. In addition, peripheral blood sampling at each visit was  
400 performed to measure plasma HIV RNA, CD4+ T cell count, and clinical labs (complete blood  
401 count, metabolic panel), as well as blood for storage - PBMCs and plasma. For a subset of  
402 individuals who reported potential PrEP overlap with HIV EDDI, participants were consented  
403 and co-enrolled in the SeroPrEP study and dried blood spot and hair were collected to confirm  
404 PrEP use. Finally, some individuals were invited to participate in optional sub-studies, which  
405 included leukapheresis and lymphoid tissue sampling (rectal and ileal biopsies, lymph node fine  
406 needle aspirate) after 12 months of ART suppression (data not included here in this paper). All  
407 participants provided written informed consent, and the institutional review board of UCSF  
408 approved the research.

409

## 410 **HIV reservoir quantification**

411           There is currently no “gold standard” for measuring the HIV reservoir. Moreover, the HIV  
412 reservoir largely consists of “defective” virus that harbors mutations prohibiting the production of  
413 infectious virus<sup>63,64</sup>. The frequencies of HIV intact and defective (3' and 5') DNA were quantified  
414 using the intact proviral DNA assay (PDA), as previously described<sup>72</sup>. Briefly, CD4+ T cells  
415 were isolated from cryopreserved PBMCs (EasySep Human CD4+ T cell Enrichment Kit,  
416 Stemcell Technologies), with cell count, viability, and purity assessed by flow cytometry both  
417 before and after selection. Negatively selected CD4+ T cells were recovered for the samples,  
418 and genomic DNA was extracted using the QIAamp DNA Mini Kit (Qiagen). DNA concentration  
419 and quality were determined by fluorometry (Qubit dsDNA BR Assay Kit, Thermo Fisher  
420 Scientific) and ultraviolet-visible (UV/VIS) spectrophotometry (QIAxpert, Qiagen). The frequency  
421 of “intact” HIV provirus (i.e., estimating the potentially replication-competent reservoir) was  
422 determined using two multiplex digital droplet polymerase chain reaction (ddPCR) assays  
423 performed in parallel: (1) the HIV-1 Proviral Discrimination reaction which distinguishes intact  
424 from defective provirus via two strategically placed amplicons in HIV psi and RRE regions as  
425 well as a hypermutation discrimination probe, and (2) the Copy Reference/Shearing reaction,  
426 which quantifies DNA shearing and input diploid cell equivalents using the human *RPP30* gene  
427<sup>72</sup>. All ddPCR reactions were assembled via automated liquid handles to maximize  
428 reproducibility and analyzed using the BioRad QX200 AutoDG Digital Droplet PCR system  
429 (BioRad). Up to 700 ng of genomic DNA were analyzed per reaction, and final input DNA  
430 concentrations were dependent upon the concentration of recovered DNA. Samples were batch  
431 processed and analyzed, including negative controls from uninfected donors and J-Lat full-  
432 length clone 6.3 (E. Verdin, Gladstone Institutes and UCSF, San Francisco, CA, USA) cells as  
433 positive controls, as previously described. Across the >500 IPDA measurements performed, we

434 interrogated a median of  $4.8 \times 10^5$  CD4+ T cell genomes per assay and observed a median  
435 DNA shearing index (DSI) of 0.40.

436

## 437 **Statistical Methods**

438 We developed a novel semiparametric biphasic decay model to estimate the rate of  
439 change of HIV DNA over time in  $\log_{10}$  copies per  $10^6$  CD4+ T cells:

$$\log_{10}(I_{it}) \sim f_1(T_{it}; \tau, \beta_1, \beta_2) + E_i \cdot f_2(T_{it}; \tau, \beta_3, \beta_4) + f_3(C_i) + f_4(V_i) + \mu_i. \#(1)$$

440 In equation (1),  $I_{it}$  represents either the intact or defective HIV DNA counts, of the  $i$ -th  
441 participant at  $t$ -th visit. The number of weeks since ART initiation is denoted  $T_{it}$ . The model  
442 additionally controls for baseline clinical information defined as the initial CD4+ T cell count,  $C_i$ ,  
443 pre-ART viral load,  $V_i$ , and the estimated time between HIV infection and ART initiation,  $E_i$ . The  
444 delay in ART initiation is centered to have a mean of zero for later analysis; this offset is  
445 approximately 60 days in our cohort. Participant-level random effects are denoted  $\mu_i$ . Building  
446 on existing models,<sup>3,48</sup> we parameterize the decay as a continuous, linear spline with a single  
447 knot at  $\tau$ :  $f_1(T_{it}; \tau, \beta_1, \beta_2) = \beta_1 \cdot \min\{T_{it}, \tau\} + \beta_2 \cdot \min\{T_{it} - \tau, 0\}$ . Using this parameterization, we  
448 can directly interpret  $\beta_1$  as the decay rate before  $\tau$  and  $\beta_2$  as the decay rate after  $\tau$ ; we use the  
449 same parameterization for  $f_2(T_{it}; \tau, \beta_3, \beta_4)$  but with different  $\beta$  values. We use a cubic spline with  
450 20 regularly spaced knots for both  $f_3(C_i)$  and  $f_4(V_i)$ . Once  $\tau$  is fixed, model fitting is performed  
451 using least-squares regression. When testing our model against monophasic and triphasic  
452 models, we used either linear terms or linear splines with two knots for  $f_1$  and  $f_2$  respectively.

453 The estimation of the inflection point,  $\tau$ , is done by minimizing the model's mean  
454 absolute prediction error. We fixed a grid of candidate  $\tau$  values from 0 weeks to 25 weeks, by  
455 half-week. The mean absolute prediction error was estimated using leave-one-out cross-  
456 validation calculated as

$$Error(\tau) = \sum_{i,t} \left| \log_{10}(I_{it}) - \log_{10}(\hat{I}_{it}^{(-i)}) \right|, \#(2)$$

457 where  $\hat{I}_{it}^{(-i)}$  denotes the predicted HIV DNA counts for patient  $i$  at time  $t$  using the model fit with  
 458 every patient except patient  $i$ . This loss metric was also used to estimate the two knots in the  
 459 triphasic model. Akaike information criteria (AIC) was used to compare the fits of the mono-, bi-,  
 460 and triphasic models.

461 Half-life estimates and their confidence intervals are computed using the multivariate  
 462 delta method. During the first decay phase, we are interested in estimating the baseline half-life  
 463 in months and the adjustment to the half-life in months due to delay in ART initiation. The half-  
 464 life (in months) before  $\tau$  is calculated as

$$t_{\frac{1}{2}}(E_i) = -\frac{0.25 \log_{10}(2)}{\beta_1 + \beta_2 E_i} = -\frac{0.25 \log_{10}(2)}{\beta_1} + \frac{0.25 \log_{10}(2) \beta_2 E_i}{\beta_1^2} + O(E_i^2), \#(3)$$

465 where the second equality is the degree-one Taylor series about  $E_i = 0$ ; this is the reason we  
 466 center  $E_i$  in our pre-processing. Thus we are interested in estimating the base-line half-life  
 467  $g_1(\beta_1, \beta_2) = -0.25 \log_{10}(2) / \beta_1$  and the adjustment to half-life for every week delay in ART  
 468  $g_2(\beta_1, \beta_2) = 0.25 \log_{10}(2) \beta_2 / \beta_1^2$ . Appealing the asymptotic normality of our parameter  
 469 estimates and the multivariate delta method, we get the following asymptotic distribution for our  
 470 half-life estimates:

$$\sqrt{n} \left( \begin{bmatrix} g_1(\hat{\beta}_1, \hat{\beta}_2) \\ g_2(\hat{\beta}_1, \hat{\beta}_2) \end{bmatrix} - \begin{bmatrix} g_1(\beta_1, \beta_2) \\ g_2(\beta_1, \beta_2) \end{bmatrix} \right) \xrightarrow{d} N \left( \begin{pmatrix} 0 \\ 0 \end{pmatrix}, J \Sigma J^T \right) \#(4)$$

$$J = 0.25 \log_{10}(2) \begin{bmatrix} \frac{1}{\beta_1^2} & 0 \\ -2 \frac{\beta_2}{\beta_1^2} & \frac{1}{\beta_1^2} \end{bmatrix} \#(5)$$

471 where  $\Sigma$  is the covariance between  $\beta_1$  and  $\beta_2$ , and  $J$  is the Jacobian matrix of  $g(\beta_1, \beta_2)$ . We plug-  
 472 in  $\hat{\Sigma}$ , along with  $\hat{\beta}_1$  and  $\hat{\beta}_2$  from our model to estimate the asymptotic confidence intervals for  
 473 base-line half-life and adjustment to half-life for delay in ART initiation. Percent decay per week

474 before  $\tau$  is calculated using the transformation  $h(\beta_1) = -100(2^{\beta_1} - 1)$ ; the negative sign  
475 accounts for the directionality of the decay. These calculations are the same for estimates of the  
476 half-life after  $\tau$ .

**Table 1. Baseline Characteristics of the UCSF Treat Acute Study Population.** Medians with interquartile ranges and frequencies with percentages are shown.


<b>UCSF Treat Acute HIV Cohort</b>	<b>N=67</b>
Days from estimated HIV acquisition to ART initiation	32.0 (22.3 – 89.8)
Initial CD4+ T-cell count (cells/mm <sup>3</sup> )	505 (350 – 670)
Pre-ART plasma HIV RNA (log <sub>10</sub> copies)	4.85 (3.69 – 5.65)
Age	30.0 (25.5 – 38.0)
Gender	
Male	65 (97.0%)
Female	1 (0.01%)
Transgender Woman	1 (0.01%)
Race/ethnicity	
White	21 (31.8%)
Latinx	20 (30.3%)
Asian	14 (21.2%)
Black	10 (15.2%)
Other	1 (1.5%)
Prior pre-exposure prophylaxis (PrEP)	28 (41.8%)
HIV acquisition/PrEP overlap <10 days	14 (20.1%)
PrEP initiated but already acquired HIV	8 (11.9%)
HIV acquired on PrEP <sup>a</sup>	6 (9.0%)
Referral HIV testing sites	
SF Department Public Health (%)	28 (41.8%)
Community-Based Organization (%)	29 (43.2%)
Private Health Clinics (%)	10 (14.9%)
Unstably housed	2 (3.0%)

<sup>a</sup> Median baseline plasma log<sub>10</sub>HIV RNA = 2.2 copies/mL.


**Figure 1. Fitted models match observed HIV reservoir patterns for HIV intact and defective DNA.**

The decay patterns for each participant are shown as thin grey lines, while the decay pattern for the model-predicted average participant is shown as the thick black lines. Biphasic decay patterns were observed for HIV intact (left panel) and total combined (3' plus 5') defective (right panel) (a). For defective HIV DNA, the biphasic decay pattern was observed more strongly for 5' but also seen with 3' defective DNA (b). Average predicted participant predictions were made by taking the mean of  $E_i$  (estimated time between HIV infection and ART initiation),  $C_i$  (initial CD4+ T cell count), and  $V_i$  ( $\log_{10}$  pre-ART plasma viral load) across participants from our final model.


**a.**



**b.**




**Figure 2. An inflection point ( $\tau = 5$  weeks) was chosen from a grid from 0 weeks to 24 weeks, by half-weeks. Results are shown for both intact (a) and defective (b) HIV DNA decay models, respectively. The biphasic decay model's inflection point was tuned by estimating the  $\tau$  that minimized prediction error measured by leave-one-out mean absolute error (MAE, upper panels) and leave-one-out mean squared error (MSE, lower panels). The best  $\tau$  for each loss (red point) is shown in relation to the final model's selected inflection point of  $\tau = 5$  weeks as reference (vertical dashed line).**






**Figure 3. Lower pre-ART viral load and higher initial CD4+ T counts are associated with lower HIV DNA reservoirs in fitted spline models.** Fitted spline models with corresponding 95% confidence intervals for HIV intact (a) and defective (b) DNA plotted against  $\log_{10}$  pre-ART viral load (left panel) and initial CD4+ T cell count (right panel). The fitted spline models are plotted in red with corresponding 95% confidence intervals denoted by blue dashed lines. Lower intact HIV DNA reservoirs (a) were associated with lower pre-ART viral load and higher initial CD4+ T counts. For example, a participant with an initial CD4+ T cell count of 900 cells/mm<sup>3</sup> was predicted to have ~10 times smaller HIV intact reservoir than a participant with an initial CD4+ T cell count of 300 cells/mm<sup>3</sup>. Similar patterns were observed for HIV defective DNA, but the fitted splines were less linear (b).

**a.**




**b.**




**Figure 4. Clinical factors influence HIV intact and defective DNA decay rates.** Faster decay rates were observed among individuals with earlier ART initiation (a), higher CD4+ T cell count (b), and lower pre-ART viral load (c). Left and right panels show decay rates for HIV intact and defective DNA, respectively. Individual participant decay rates shown in thin black lines, and cohort medians shown by bold black solid or dashed lines.


**a.**



**b.**




**c.**



1 **Figure 5. Model predictions demonstrate the impact of clinical factors on HIV DNA decay**  
2 **rates.** Average model predictions were made by bootstrapping 300 random participants and  
3 predicting their HIV DNA counts, the model predictions were then averaged within each stratum  
4 (tertiles of clinical predictors of HIV reservoir size: timing of ART initiation, initial CD4+ T cell  
5 count, and pre-ART viral load). The strata for each key clinical parameter demonstrated that  
6 slight changes in these clinical parameters (e.g., by tertiles) significantly influence reservoir  
7 decay rates for both intact and defective DNA. Predicted reservoir size 95% confidence limits  
8 were narrower for the first phase of decay (weeks 0-5) relative to the second phase of decay  
9 (weeks 5-24).

10

11 **a.**



12

13


14

15

16


17

18 **b.**



19

20 **c.**



21

22

## 23 REFERENCES

- 24 1 Chun, T. W. *et al.* Rebound of plasma viremia following cessation of antiretroviral  
25 therapy despite profoundly low levels of HIV reservoir: implications for  
26 eradication. *AIDS* **24**, 2803-2808 (2010).  
27 <https://doi.org/10.1097/QAD.0b013e328340a239>
- 28 2 Hocqueloux, L. *et al.* Long-term immunovirologic control following antiretroviral  
29 therapy interruption in patients treated at the time of primary HIV-1 infection.  
30 *AIDS* **24**, 1598-1601 (2010). <https://doi.org/10.1097/qad.0b013e32833b61ba>
- 31 3 White, J. A. *et al.* Complex decay dynamics of HIV virions, intact and defective  
32 proviruses, and 2LTR circles following initiation of antiretroviral therapy. *Proc Natl*  
33 *Acad Sci U S A* **119** (2022). <https://doi.org/10.1073/pnas.2120326119>
- 34 4 Perelson, A. S. *et al.* Decay characteristics of HIV-1-infected compartments  
35 during combination therapy. *Nature* **387**, 188-191 (1997).  
36 <https://doi.org/10.1038/387188a0>
- 37 5 Kwon, K. J. & Siliciano, R. F. HIV persistence: clonal expansion of cells in the  
38 latent reservoir. *J Clin Invest* **127**, 2536-2538 (2017).  
39 <https://doi.org/10.1172/JCI95329>
- 40 6 Finzi, D. & Siliciano, R. F. Viral dynamics in HIV-1 infection. *Cell* **93**, 665-671  
41 (1998). [https://doi.org/10.1016/s0092-8674\(00\)81427-0](https://doi.org/10.1016/s0092-8674(00)81427-0)
- 42 7 Chomont, N. *et al.* HIV reservoir size and persistence are driven by T cell survival  
43 and homeostatic proliferation. *Nature medicine* **15**, 893-900 (2009).  
44 <https://doi.org/10.1038/nm.1972>

- 45 8 Yukl, S. A. *et al.* Differences in HIV burden and immune activation within the gut  
46 of HIV-positive patients receiving suppressive antiretroviral therapy. *The Journal*  
47 *of infectious diseases* **202**, 1553-1561 (2010). <https://doi.org/10.1086/656722>
- 48 9 Archin, N. M. *et al.* Administration of vorinostat disrupts HIV-1 latency in patients  
49 on antiretroviral therapy. *Nature* **487**, 482-485 (2012).  
50 <https://doi.org/10.1038/nature11286>
- 51 10 Elliott, J. H. *et al.* Short-term administration of disulfiram for reversal of latent HIV  
52 infection: a phase 2 dose-escalation study. *Lancet HIV* **2**, e520-529 (2015).  
53 [https://doi.org/10.1016/S2352-3018\(15\)00226-X](https://doi.org/10.1016/S2352-3018(15)00226-X)
- 54 11 Rasmussen, T. A. *et al.* Panobinostat, a histone deacetylase inhibitor, for latent-  
55 virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a  
56 phase 1/2, single group, clinical trial. *Lancet HIV* **1**, e13-21 (2014).  
57 [https://doi.org/10.1016/S2352-3018\(14\)70014-1](https://doi.org/10.1016/S2352-3018(14)70014-1)
- 58 12 Elliott, J. H. *et al.* Activation of HIV transcription with short-course vorinostat in  
59 HIV-infected patients on suppressive antiretroviral therapy. *PLoS pathogens* **10**,  
60 e1004473 (2014). <https://doi.org/10.1371/journal.ppat.1004473>
- 61 13 Gay, C. L. *et al.* Assessing the impact of AGS-004, a dendritic cell-based  
62 immunotherapy, and vorinostat on persistent HIV-1 Infection. *Sci Rep* **10**, 5134  
63 (2020). <https://doi.org/10.1038/s41598-020-61878-3>
- 64 14 Fidler, S. *et al.* Antiretroviral therapy alone versus antiretroviral therapy with a  
65 kick and kill approach, on measures of the HIV reservoir in participants with  
66 recent HIV infection (the RIVER trial): a phase 2, randomised trial. *Lancet* **395**,  
67 888-898 (2020). [https://doi.org/10.1016/S0140-6736\(19\)32990-3](https://doi.org/10.1016/S0140-6736(19)32990-3)

- 68 15 Gutierrez, C. *et al.* Bryostatins for latent virus reactivation in HIV-infected  
69 patients on antiretroviral therapy. *AIDS* **30**, 1385-1392 (2016).  
70 <https://doi.org/10.1097/QAD.0000000000001064>
- 71 16 Vibholm, L. *et al.* Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts  
72 Innate Immunity and Plasma Viremia in Individuals With Human  
73 Immunodeficiency Virus Infection. *Clin Infect Dis* **64**, 1686-1695 (2017).  
74 <https://doi.org/10.1093/cid/cix201>
- 75 17 Riddler, S. A. *et al.* Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune  
76 Activation in Virally Suppressed Adults Living With Human Immunodeficiency  
77 Virus-1. *Clin Infect Dis* **72**, e815-e824 (2021).  
78 <https://doi.org/10.1093/cid/ciaa1534>
- 79 18 Elliott, J. H. *et al.* Short-term administration of disulfiram for reversal of latent HIV  
80 infection: a phase 2 dose-escalation study. *Lancet HIV* **2**, e520-529 (2015).  
81 [https://doi.org/10.1016/S2352-3018\(15\)00226-X](https://doi.org/10.1016/S2352-3018(15)00226-X)
- 82 19 Bar, K. J. *et al.* Effect of HIV Antibody VRC01 on Viral Rebound after Treatment  
83 Interruption. *N Engl J Med* **375**, 2037-2050 (2016).  
84 <https://doi.org/10.1056/NEJMoa1608243>
- 85 20 Gunst, J. D. *et al.* Early intervention with 3BNC117 and romidepsin at  
86 antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized  
87 trial. *Nat Med* **28**, 2424-2435 (2022). <https://doi.org/10.1038/s41591-022-02023-7>
- 88 21 Gunst, J. D. *et al.* in *Conference on Retroviruses and Opportunistic Infections*.
- 89 22 Archin, N. M. *et al.* Immediate antiviral therapy appears to restrict resting CD4+  
90 cell HIV-1 infection without accelerating the decay of latent infection. *Proc Natl*



- 91 *Acad Sci U S A* **109**, 9523-9528 (2012).
- 92 <https://doi.org/10.1073/pnas.1120248109>
- 93 23 Buzon, M. J. *et al.* Long-term antiretroviral treatment initiated at primary HIV-1  
94 infection affects the size, composition, and decay kinetics of the reservoir of HIV-  
95 1-infected CD4 T cells. *J Virol* **88**, 10056-10065 (2014).
- 96 <https://doi.org/10.1128/JVI.01046-14>
- 97 24 Chun, T. W. *et al.* Early establishment of a pool of latently infected, resting  
98 CD4(+) T cells during primary HIV-1 infection. *Proc Natl Acad Sci U S A* **95**,  
99 8869-8873 (1998). <https://doi.org/10.1073/pnas.95.15.8869>
- 100 25 Strain, M. C. *et al.* Effect of treatment, during primary infection, on establishment  
101 and clearance of cellular reservoirs of HIV-1. *J Infect Dis* **191**, 1410-1418 (2005).
- 102 <https://doi.org/10.1086/428777>
- 103 26 Hocqueloux, L., Saez-Cirion, A. & Rouzioux, C. Immunovirologic control 24  
104 months after interruption of antiretroviral therapy initiated close to HIV  
105 seroconversion. *JAMA Intern Med* **173**, 475-476 (2013).
- 106 <https://doi.org/10.1001/jamainternmed.2013.2176>
- 107 27 Ananworanich, J. *et al.* Virological and immunological characteristics of HIV-  
108 infected individuals at the earliest stage of infection. *J Virus Erad* **2**, 43-48 (2016).
- 109 28 Ananworanich, J. *et al.* Impact of multi-targeted antiretroviral treatment on gut T  
110 cell depletion and HIV reservoir seeding during acute HIV infection. *PLoS One* **7**,  
111 e33948 (2012). <https://doi.org/10.1371/journal.pone.0033948>
- 112 29 Deleage, C. *et al.* Impact of early cART in the gut during acute HIV infection. *JCI*  
113 *Insight* **1** (2016). <https://doi.org/10.1172/jci.insight.87065>



- 114 30 Takata, H. *et al.* Long-term antiretroviral therapy initiated in acute HIV infection  
115 prevents residual dysfunction of HIV-specific CD8(+) T cells. *EBioMedicine* **84**,  
116 104253 (2022). <https://doi.org/10.1016/j.ebiom.2022.104253>
- 117 31 Oxenius, A. *et al.* Early highly active antiretroviral therapy for acute HIV-1  
118 infection preserves immune function of CD8+ and CD4+ T lymphocytes. *Proc*  
119 *Natl Acad Sci U S A* **97**, 3382-3387 (2000).  
120 <https://doi.org/10.1073/pnas.97.7.3382>
- 121 32 Streeck, H. *et al.* Immunological and virological impact of highly active  
122 antiretroviral therapy initiated during acute HIV-1 infection. *J Infect Dis* **194**, 734-  
123 739 (2006). <https://doi.org/10.1086/503811>
- 124 33 Namazi, G. *et al.* The Control of HIV After Antiretroviral Medication Pause  
125 (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. *J*  
126 *Infect Dis* **218**, 1954-1963 (2018). <https://doi.org/10.1093/infdis/jiy479>
- 127 34 Peluso, M. J. *et al.* Differential decay of intact and defective proviral DNA in HIV-  
128 1-infected individuals on suppressive antiretroviral therapy. *JCI Insight* **5** (2020).  
129 <https://doi.org/10.1172/jci.insight.132997>
- 130 35 Gandhi, R. T. *et al.* Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral  
131 Therapy. *J Infect Dis* **223**, 225-233 (2021). <https://doi.org/10.1093/infdis/jiaa532>
- 132 36 Gandhi, R. T. *et al.* Varied Patterns of Decay of Intact Human Immunodeficiency  
133 Virus Type 1 Proviruses Over 2 Decades of Antiretroviral Therapy. *J Infect Dis*  
134 **227**, 1376-1380 (2023). <https://doi.org/10.1093/infdis/jiad039>

- 135 37 Antar, A. A. *et al.* Longitudinal study reveals HIV-1-infected CD4+ T cell  
136 dynamics during long-term antiretroviral therapy. *J Clin Invest* **130**, 3543-3559  
137 (2020). <https://doi.org/10.1172/JCI135953>
- 138 38 Shi, L. *et al.* in *International AIDS Society Conference on HIV Science*.
- 139 39 Ananworanich, J. *et al.* HIV DNA Set Point is Rapidly Established in Acute HIV  
140 Infection and Dramatically Reduced by Early ART. *EBioMedicine* **11**, 68-72  
141 (2016). <https://doi.org/10.1016/j.ebiom.2016.07.024>
- 142 40 Crowell, T. A. *et al.* Virologic failure is uncommon after treatment initiation during  
143 acute HIV infection. *AIDS* **30**, 1943-1950 (2016).  
144 <https://doi.org/10.1097/QAD.0000000000001148>
- 145 41 Lee SA, H. T., Gandhi M, Coffey S, Harting H, Hoh R, Peluso MJ, Siegel D,  
146 Crouch P, Scott H, Cohen SD, Sachdev D, Bacon O, Busch M, Pilcher C,  
147 Buchbinder S, Havlir DV, Deeks SG. in *International AIDS Society Conference*.
- 148 42 Grebe, E. *et al.* Interpreting HIV diagnostic histories into infection time estimates:  
149 analytical framework and online tool. *BMC Infect Dis* **19**, 894 (2019).  
150 <https://doi.org/10.1186/s12879-019-4543-9>
- 151 43 Fiebig, E. W. *et al.* Dynamics of HIV viremia and antibody seroconversion in  
152 plasma donors: implications for diagnosis and staging of primary HIV infection.  
153 *AIDS* **17**, 1871-1879 (2003).  
154 <https://doi.org/10.1097/01.aids.0000076308.76477.b8>
- 155 44 Keele, B. F. *et al.* Identification and characterization of transmitted and early  
156 founder virus envelopes in primary HIV-1 infection. *Proc Natl Acad Sci U S A*  
157 **105**, 7552-7557 (2008). <https://doi.org/10.1073/pnas.0802203105>

- 158 45 Prevention., C. f. D. C. a. HIV Surveillance Report.  
159 <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Published May 2022.  
160 Accessed Nov 2, 2023., (2020).
- 161 46 Buchbinder, S. P. & Havlir, D. V. Getting to Zero San Francisco: A Collective  
162 Impact Approach. *J Acquir Immune Defic Syndr* **82 Suppl 3**, S176-S182 (2019).  
163 <https://doi.org/10.1097/QAI.0000000000002200>
- 164 47 Cohen, S. E. *et al.* Acquisition of tenofovir-susceptible, emtricitabine-resistant  
165 HIV despite high adherence to daily pre-exposure prophylaxis: a case report.  
166 *Lancet HIV* (2018). [https://doi.org/10.1016/S2352-3018\(18\)30288-1](https://doi.org/10.1016/S2352-3018(18)30288-1)
- 167 48 McMyn, N. F. *et al.* The latent reservoir of inducible, infectious HIV-1 does not  
168 decrease despite decades of antiretroviral therapy. *J Clin Invest* **133** (2023).  
169 <https://doi.org/10.1172/JCI117154>
- 170 49 Whitney, J. B. *et al.* Rapid seeding of the viral reservoir prior to SIV viraemia in  
171 rhesus monkeys. *Nature* **512**, 74-77 (2014). <https://doi.org/10.1038/nature13594>
- 172 50 Leyre, L. *et al.* Abundant HIV-infected cells in blood and tissues are rapidly  
173 cleared upon ART initiation during acute HIV infection. *Sci Transl Med* **12** (2020).  
174 <https://doi.org/10.1126/scitranslmed.aav3491>
- 175 51 Ananworanich, J. *et al.* Virological and immunological characteristics of HIV-  
176 infected individuals at the earliest stage of infection. *J Virus Erad* **2**, 43-48 (2016).
- 177 52 Deeks, S. G. *et al.* Research priorities for an HIV cure: International AIDS Society  
178 Global Scientific Strategy 2021. *Nat Med* **27**, 2085-2098 (2021).  
179 <https://doi.org/10.1038/s41591-021-01590-5>

- 180 53 Gay, C. L. *et al.* Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1  
181 Infected Participants on Suppressive Antiretroviral Therapy. *J Infect Dis* **215**,  
182 1725-1733 (2017). <https://doi.org/10.1093/infdis/jix191>
- 183 54 Gay, C. L. *et al.* Suspected Immune-Related Adverse Events With an Anti-PD-1  
184 Inhibitor in Otherwise Healthy People With HIV. *J Acquir Immune Defic Syndr* **87**,  
185 e234-e236 (2021). <https://doi.org/10.1097/QAI.0000000000002716>
- 186 55 Colston, E. *et al.* An open-label, multiple ascending dose study of the anti-CTLA-  
187 4 antibody ipilimumab in viremic HIV patients. *PLoS One* **13**, e0198158 (2018).  
188 <https://doi.org/10.1371/journal.pone.0198158>
- 189 56 Reeves, D. B. *et al.* Impact of misclassified defective proviruses on HIV reservoir  
190 measurements. *Nat Commun* **14**, 4186 (2023). [https://doi.org/10.1038/s41467-](https://doi.org/10.1038/s41467-023-39837-z)  
191 [023-39837-z](https://doi.org/10.1038/s41467-023-39837-z)
- 192 57 Reeves, D. B. *et al.* A majority of HIV persistence during antiretroviral therapy is  
193 due to infected cell proliferation. *Nat Commun* **9**, 4811 (2018).  
194 <https://doi.org/10.1038/s41467-018-06843-5>
- 195 58 Shan, L. *et al.* Transcriptional Reprogramming during Effector-to-Memory  
196 Transition Renders CD4(+) T Cells Permissive for Latent HIV-1 Infection.  
197 *Immunity* **47**, 766-775 e763 (2017). <https://doi.org/10.1016/j.immuni.2017.09.014>
- 198 59 Jain, V. *et al.* Antiretroviral therapy initiated within 6 months of HIV infection is  
199 associated with lower T-cell activation and smaller HIV reservoir size. *J Infect Dis*  
200 **208**, 1202-1211 (2013). <https://doi.org/10.1093/infdis/jit311>

- 201 60 Henrich, T. J. *et al.* HIV-1 persistence following extremely early initiation of  
202 antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.  
203 *PLoS Med* **14**, e1002417 (2017). <https://doi.org/10.1371/journal.pmed.1002417>
- 204 61 Chun, T. W. *et al.* Decay of the HIV reservoir in patients receiving antiretroviral  
205 therapy for extended periods: implications for eradication of virus. *J Infect Dis*  
206 **195**, 1762-1764 (2007). <https://doi.org/10.1086/518250>
- 207 62 Jain, V., Hartogensis, W., Bacchetti, P., Hunt, P.W., Hatano, H., Sinclair, E.,  
208 Epling, L., Lee, T-H., Busch, M., McCune, J.M., Pilcher, C.D., Hecht, F.M., and  
209 Deeks, S.G. . Antiretroviral therapy initiated within 6 months of HIV infection is  
210 associated with lower T-cell activation and smaller HIV reservoir size. *Journal of*  
211 *Infectious Diseases* **In press** (2013).
- 212 63 Ho, Y. C. *et al.* Replication-competent noninduced proviruses in the latent  
213 reservoir increase barrier to HIV-1 cure. *Cell* **155**, 540-551 (2013).  
214 <https://doi.org/10.1016/j.cell.2013.09.020>
- 215 64 Bruner, K. M. *et al.* Defective proviruses rapidly accumulate during acute HIV-1  
216 infection. *Nat Med* **22**, 1043-1049 (2016). <https://doi.org/10.1038/nm.4156>
- 217 65 Pinzone, M. R. *et al.* Longitudinal HIV sequencing reveals reservoir expression  
218 leading to decay which is obscured by clonal expansion. *Nat Commun* **10**, 728  
219 (2019). <https://doi.org/10.1038/s41467-019-08431-7>
- 220 66 Gondim, M. V. P. *et al.* Heightened resistance to host type 1 interferons  
221 characterizes HIV-1 at transmission and after antiretroviral therapy interruption.  
222 *Sci Transl Med* **13** (2021). <https://doi.org/10.1126/scitranslmed.abd8179>

- 223 67 Finzi, D. *et al.* Identification of a reservoir for HIV-1 in patients on highly active  
224 antiretroviral therapy. *Science* **278**, 1295-1300 (1997).  
225 <https://doi.org/10.1126/science.278.5341.1295>
- 226 68 Siliciano, J. D. *et al.* Long-term follow-up studies confirm the stability of the latent  
227 reservoir for HIV-1 in resting CD4+ T cells. *Nature medicine* **9**, 727-728 (2003).  
228 <https://doi.org/10.1038/nm880>
- 229 69 Kumar, M. R. *et al.* Biphasic decay of intact SHIV genomes following initiation of  
230 antiretroviral therapy complicates analysis of interventions targeting the reservoir.  
231 *Proc Natl Acad Sci U S A* **120**, e2313209120 (2023).  
232 <https://doi.org/10.1073/pnas.2313209120>
- 233 70 Martin, A. R. *et al.* Similar Frequency and Inducibility of Intact Human  
234 Immunodeficiency Virus-1 Proviruses in Blood and Lymph Nodes. *J Infect Dis*  
235 **224**, 258-268 (2021). <https://doi.org/10.1093/infdis/jiaa736>
- 236 71 Simonetti, F. R. *et al.* Intact proviral DNA assay analysis of large cohorts of  
237 people with HIV provides a benchmark for the frequency and composition of  
238 persistent proviral DNA. *Proc Natl Acad Sci U S A* **117**, 18692-18700 (2020).  
239 <https://doi.org/10.1073/pnas.2006816117>
- 240 72 Bruner, K. M. *et al.* A quantitative approach for measuring the reservoir of latent  
241 HIV-1 proviruses. *Nature* **566**, 120-125 (2019). [https://doi.org/10.1038/s41586-](https://doi.org/10.1038/s41586-019-0898-8)  
242 [019-0898-8](https://doi.org/10.1038/s41586-019-0898-8)
- 243  
244  
245  
246

247 **FIGURE LEGENDS**

248 **Table 1. Baseline Characteristics of the UCSF Treat Acute Study Population.** Medians with  
249 interquartile ranges and frequencies with percentages are shown.

250

251 **Figure 1. Fitted models match observed HIV reservoir patterns for HIV intact and**  
252 **defective DNA.** The decay patterns for each participant are shown as thin grey lines, while the  
253 decay pattern for the model-predicted average participant is shown as the thick black lines.  
254 Biphasic decay patterns were observed for HIV intact (left panel) and total combined (3' plus 5')  
255 defective (right panel) (a). For defective HIV DNA, the biphasic decay pattern was observed  
256 more strongly for 5' but also seen with 3' defective DNA (b). Average predicted participant  
257 predictions were made by taking the mean of  $E_i$  (estimated time between HIV infection and ART  
258 initiation),  $C_i$  (initial CD4+ T cell count), and  $V_i$  ( $\log_{10}$  pre-ART plasma viral load) across  
259 participants from our final model.

260

261 **Figure 2. An inflection point ( $\tau = 5$  weeks) was chosen from a grid from 0 weeks to 24**  
262 **weeks, by half-weeks.** Results are shown for both intact (a) and defective (b) HIV DNA decay  
263 models, respectively. The biphasic decay model's inflection point was tuned by estimating the  $\tau$   
264 that minimized prediction error measured by leave-one-out mean absolute error (MAE, upper  
265 panels) and leave-one-out mean squared error (MSE, lower panels). The best  $\tau$  for each loss  
266 (red point) is shown in relation to the final model's selected inflection point of  $\tau = 5$  weeks as  
267 reference (vertical dashed line).

268

269 **Figure 3. Lower pre-ART viral load and higher initial CD4+ T counts are associated with**  
270 **lower HIV DNA reservoirs in fitted spline models.** Fitted spline models with corresponding  
271 95% confidence intervals for HIV intact (a) and defective (b) DNA plotted against  $\log_{10}$  pre-ART

272 viral load (left panel) and initial CD4+ T cell count (right panel). The fitted spline models are  
273 plotted in red with corresponding 95% confidence intervals denoted by blue dashed lines. Lower  
274 intact HIV DNA reservoirs (a) were associated with lower pre-ART viral load and higher initial  
275 CD4+ T counts. For example, a participant with an initial CD4+ T cell count of 900 cells/mm<sup>3</sup>  
276 was predicted to have ~10 times smaller HIV intact reservoir than a participant with an initial  
277 CD4+ T cell count of 300 cells/mm<sup>3</sup>. Similar patterns were observed for HIV defective DNA, but  
278 the fitted splines were less linear (b).

279

280 **Figure 4. Clinical factors influence HIV intact and defective DNA decay rates.** Faster decay  
281 rates were observed among individuals with earlier ART initiation (a), higher CD4+ T cell count  
282 (b), and lower pre-ART viral load (c). Left and right panels show decay rates for HIV intact and  
283 defective DNA, respectively. Individual participant decay rates shown in thin black lines, and  
284 cohort medians shown by bold black solid or dashed lines.

285

286 **Figure 5. Model predictions demonstrate the impact of clinical factors on HIV DNA decay**  
287 **rates.** Average model predictions were made by bootstrapping 300 random participants and  
288 predicting their HIV DNA counts, the model predictions were then averaged within each stratum  
289 (tertiles of clinical predictors of HIV reservoir size: timing of ART initiation, initial CD4+ T cell  
290 count, and pre-ART viral load). The strata for each key clinical parameter demonstrated that  
291 slight changes in these clinical parameters (e.g., by tertiles) significantly influence reservoir  
292 decay rates for both intact and defective DNA. Predicted reservoir size 95% confidence limits  
293 were narrower for the first phase of decay (weeks 0-5) relative to the second phase of decay  
294 (weeks 5-24).

295

296 **Supplementary Figure 1. The UCSF Treat Acute HIV cohort study participants.** A total of  
297 67 participants met inclusion criteria for acute HIV, defined as <100 days since the estimated



298 date of detected HIV infection (EDDI) using the Infection Dating Tool ([https://tools.incidence-](https://tools.incidence-estimation.org/idt/)  
299 [estimation.org/idt/](https://tools.incidence-estimation.org/idt/)). The numbers of study participants by Fiebig stages (I-V) of HIV recency are  
300 also shown (<https://doi.org/10.1097/01.aids.0000076308.76477.b8>). PrEP = Pre-exposure  
301 prophylaxis with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC).

302

303 **Supplementary Figure 2. Calculation of estimated dates of detected HIV infection.** The  
304 estimated dates of detected HIV infection (EDDI), along with a “confidence interval” for early  
305 probable (EP-EDDI) and late probable (LP-EDDI) dates, were calculated using participants’  
306 clinical test results as well as baseline study visit confirmatory assay results.

307

308 **Supplementary Figure 3. Fiebig and race/ethnicity distribution within the UCSF Treat**  
309 **Acute HIV cohort.** The distribution of study participants in the UCSF Treat Acute HIV cohort, by  
310 timing of ART initiation (a) and self-reported race/ethnicity (b). A total of 67 participants met  
311 inclusion criteria for acute HIV, defined as <100 days since the estimated date of detected HIV  
312 infection (EDDI) using the Infection Dating Tool (<https://tools.incidence-estimation.org/idt/>). The  
313 proportions of study participants by Fiebig stages (I-V) are also shown in (a).

314

315 **Supplementary Figure 4. HIV-1/2 test results for study participants.** The proportion of study  
316 participants with either negative and/or indeterminate test results for HIV-1/2 p24  
317 antigen/antibody assay (Architect) (a) and HIV-1/2 differentiation (Geenius) antibody assay (b)  
318 at baseline study visit were consistent with rates with our San Francisco Department of Public  
319 Health rates (27% and 28%, respectively).

320

321 **Supplementary Figure 5. Observed HIV intact and defective reservoir decays highlighting**  
322 **participants reporting a history of PrEP use.** Most participants did not report PrEP overlap

323 near the time of HIV diagnosis (grey lines). A subset of participants reported PrEP overlap  
324 within 10 days of HIV diagnosis; N=6 participants acquired HIV while already taking PrEP  
325 (yellow lines) and N=8 participants were prescribed PrEP but were found to already have  
326 acquired HIV (blue lines).

327  
328 **Supplementary Figure 6. Semiparametric monophasic, biphasic, and triphasic**  
329 **generalized additive model fit comparison suggest biphasic model has the most**  
330 **parsimonious fit.** Infection points were selected by minimizing the leave-one-out prediction  
331 mean absolute error (MAE) for each model and both HIV DNA assays. Tuning results for the  
332 triphasic model show that the best model (emphasized in red) either has two knots near each  
333 other or one knot near zero (a) suggesting that it is similar in shape to a biphasic model; leave-  
334 one-out prediction mean squared error (MSE) is proved for extra support. The Akaike  
335 information criteria (AIC) value and 95% confidence interval was then used to compare  
336 monophasic, biphasic, and triphasic models for both assays (b). AIC estimates and confidence  
337 intervals were found by fitting models on 500 bootstrap resampled data sets. For both HIV intact  
338 and defective DNA, the biphasic and triphasic models had relatively equivalent performance.

339  
340 **Supplementary Figure 7. Modeling using the full first year of data suggests reservoir**  
341 **decay trends continue past the first 24 weeks on ART.** 65.7% of the total study participants  
342 continued in the study beyond 24 weeks. Observed HIV reservoir patterns are shown as thin  
343 grey lines, while the decay pattern for the model-predicted average participant is shown as the  
344 thick black lines (a). Average predicted participant predictions were made by taking the mean of  
345  $E_i$  (estimated time between HIV infection and ART initiation),  $C_i$  (initial CD4+ T cell count), and  
346  $V_i$  ( $\log_{10}$  pre-ART plasma viral load) across participants. Model inflection point tuning is shown  
347 for both intact (left panels) and defective (right panels) HIV DNA decay models, respectively (b).  
348 The biphasic decay model's inflection point was tuned by estimating the  $\tau$  that minimized

349 prediction error measured by leave-one-out mean absolute deviation (MAE, upper panels) and  
350 leave-one-out mean squared error (MSE, lower panels). A grid of  $\tau$  values from weeks 0 to 52,  
351 by half-weeks, was considered as potential inflection points. The best  $\tau$  for each loss (red point)  
352 is shown in relation to the final model's selected inflection point of  $\tau = 5$  weeks as reference  
353 (vertical dashed line).

354

355 **Supplementary Figure 8. Inflection point sensitivity analyses demonstrate some**

356 **variability when excluding populations of potential outliers.** To test whether the final model

357 inflection point selection of  $\tau = 5$  weeks was influenced by potential outlier data we performed  $\tau$

358 estimation on three clinically interesting sub-populations. Separate models were fit that

359 excluded (a) participants reporting prior PrEP use (<10 days overlap between last PrEP use and

360 estimated date of detected HIV infection), (b) participants with plasma viral load “blips” (defined

361 as a one-time viral load >1000 copies/mL or two consecutive viral loads >100 copies/mL

362 between weeks 0-24), and (c) participants with sudden increases in HIV intact DNA (defined as

363 >50% increase between two consecutive measurements of HIV intact DNA during weeks 0-24).

364 A regular grid of possible  $\tau$  was used (0-26 weeks by half-week) and the leave-one-out cross-

365 validation (LOOCV) mean absolute prediction error (MAE) was computed for each candidate  $\tau$ .

366 The model attaining the best prediction error is denoted with a red point and our selected

367 inflection point ( $\tau = 5$ ) is shown with a dashed vertical line. Refer to **Supplementary Table 2** to

368 get the sample size for each sensitivity analysis and to **Supplementary Figure 9** to see which

369 patients are excluded from each sensitivity analysis.

370

371 **Supplementary Figure 9. Model estimate sensitivity analyses demonstrated that results**

372 **were overall unchanged after excluding populations of potential outliers.** The final model

373 ( $\tau = 5$  weeks) was fit on three clinically interesting sub-populations to assess if the influence of

374 potential outlier data. Separate models were fit that excluded (a) participants reporting prior  
375 PrEP use (<10 days overlap between last PrEP use and estimated date of detected HIV  
376 infection), (b) participants with plasma viral load “blips” (defined as a one-time viral load >1000  
377 copies/mL or two consecutive viral loads >100 copies/mL between weeks 0-24), and (c)  
378 participants with sudden increases in HIV intact DNA (defined as >50% increase between two  
379 consecutive measurements of HIV intact DNA during weeks 0-24). Models were fit using the  
380 cohort data (grey lines), but not the potential outlier data (red lines). The resulting predict  
381 average participant HIV reservoir decay patterns are shown as thick black lines. Refer to  
382 **Supplementary Table 2** to get the sample sizes and half-life estimates for each sensitivity  
383 analysis.

384  
385 **Supplementary Figure 10. Predicted versus observed plots show good model**  
386 **performance for both HIV intact and defective DNA.** Validation for the final models for intact  
387 and defective HIV DNA decay was initially performed by looking at the plots of predicted vs  
388 observed HIV DNA counts. These plots show that both models produce relatively unbiased  
389 estimates across the observed range of HIV DNA counts and that the residual variance in the  
390 defective reservoir is much higher than the intact reservoir. A dashed, red line at  $y=x$  is added to  
391 help interpret the model fits.

392  
393 **Supplementary Table 1. Model estimates of HIV intact and defective DNA decay rates**  
394 **from baseline models.** Baseline models include random intercepts for each participant but are  
395 otherwise unadjusted for clinical covariates. Model estimates are provided for discrete periods  
396 of ART suppression after initial treatment initiation: weeks 0 up to  $\tau = 5$  and for weeks after  $\tau$ .

397  
398 **Supplementary Table 2. Model estimates of HIV intact and defective DNA decay rates**  
399 **from models adjusted for initial CD4+ T cell count, pre-ART HIV RNA, and timing of ART**

400 **initiation.** Models also include a random intercept for each participant. Model estimates are  
401 provided for discrete periods of ART suppression after initial treatment initiation: weeks 0 up to  
402  $\tau = 5$  and for weeks after  $\tau$ .

403

404 **Supplementary Table 3. Changes in HIV decay rates of intact and defective DNA**  
405 **associated with timing of ART initiation.** Faster decay rates in both intact and defective HIV  
406 DNA during phase 1 are associated with lower delay in ART initiation. Intact, but not defective,  
407 HIV DNA have faster predicted decay rates associated with lower delay in ART initiation.

408

409 **Supplementary Table 4. Changes in the intact and defective HIV DNA reservoir size**  
410 **associated with initial CD4+ T cell count and pre-ART viral load.** Table values are  $\log_{10}$   
411 adjustments to the viral reservoir size at each clinical parameter. Higher initial CD4+ T cell count  
412 and lower pre-ART viral load are associated with smaller viral reservoirs. Additional estimates  
413 can be taken from **Figure 3**.

414